Compare Enveric Biosciences Inc (ENVB) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Tapestry, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Tapestry, Inc. trades at $161.95 (market cap $33.29B). The key difference: Tapestry, Inc. is far larger — about 5369.4× Enveric Biosciences Inc's market cap, and Tapestry, Inc. pays a 0.97% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TPR | |
|---|---|---|
Market Cap | $6.20M | $33.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $164.78 |
52-Week Low | $1.27 | $95.69 |
Enterprise Value | $1.30M | $36.15B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
TPR trades at $162.36, up 0.22% today, and is near its 52-week high with strong bullish technical signals. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. Recent news highlights AI integration and brand momentum, while analyst consensus is strongly bullish with a $190.33 price target.
Outlook remains positive driven by earnings growth and strategic initiatives, but risks include high valuation multiples and volatile cash flows. The stock offers upside to analyst targets but faces margin pressure and competitive challenges in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
